KRAS and T lymphoblastic leukemia/lymphoma: While KRAS is mutated in many tumors including non-hematopoietic malignancies, T-lymphoblastic lymphoma/leukemia (T-ALL), which accounts for up to 15% of pediatric and 25% of adult ALL cases, may have a KRAS G12D mutation.